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ABSTRACT We have previously identified and character-
ized a heparin-binding cell surface protein (heparinyheparan
sulfate-interacting protein, or HIP) present on epithelial and
endothelial cells. A synthetic peptide mimicking a heparin-
binding domain of HIP is now shown to bind a small subset of
heparin molecules with high affinity and, therefore, presum-
ably recognizes a specific structural motif in the heparin
molecule. Further analyses revealed that the heparin mole-
cules exhibiting a high affinity for the HIP peptide also show
an extremely high affinity for antithrombin III (AT-III), a
cofactor required for heparin’s anticoagulant activity. The
HIP peptide was shown to compete with AT-III for binding to
heparin and to neutralize the anticoagulant activity of heparin
in blood plasma assays. Furthermore, the heparin subfraction
that binds to the HIP peptide with high affinity exhibits an
extremely high anticoagulant activity. We conclude that al-
though the HIP peptide shows no sequence similarity with
AT-III, the two proteins recognize the same or similar struc-
tural motifs in heparin.
The glycosaminoglycans heparin (Hep) and heparan sulfate
(HS) appear to exert their biological functions through regu-
latory interactions with specific target proteins. Because of the
microheterogeneity of the sulfate substitutions of the polysac-
charides, it has been speculated that specific monosaccharide
sequences in Hep bind to selective domains in target proteins
(1–5). A Hep hexasaccharide can theoretically occur in .105
different structural forms, which allows for sufficient structural
variations, expected for an information molecule. On the other
hand, the biosynthesis of a structurally heterogeneous glycos-
aminoglycan seems to result from a series of incomplete
enzymatic reactions, raising concern about the genetic control
of glycosaminoglycan fine structure (6). At least one protein,
antithrombin III (AT-III), binds to a specific sequence present
in some Hep molecules but not in others (1–3). Other proteins,
such as the FGFs bind to Hep with surprisingly high affinity;
however, attempts to identify specific binding sites in Hep for
different growth factors have given inconclusive and some-
times conflicting results. Here we report on a synthetic peptide
derived from a cell surface HepyHS-interacting protein (HIP),
which binds to a Hep sequence that is similar or identical to
that specifically recognized by AT-III.
HIP has been identified in human uterine epithelia and a
variety of other human epithelial and endothelial cells (7, 8).
Analysis of the predicted amino acid sequence of HIP revealed
a putative HepyHS-binding motif. A synthetic peptide corre-
sponding to this motif (HIP peptide) selectively binds Hep and
certain forms of HS expressed by human cell lines and supports
attachment of a variety of mammalian adherent cell lines in a
HS-dependent fashion (S.L. and D.D.C., unpublished work).
In the current study, we used HIP peptide affinity chroma-
tography to further investigate the interactions between HIP
peptide and Hep polysaccharide chains. Our data indicate that
HIP peptide binds a subset (1–5% of total) of Hep from
commercial preparations with much higher affinity than un-
fractionated Hep. The subset of Hep that binds HIP with high
affinity (HA-Hep) is also the subset that binds AT-III with
highest affinity. Coagulation assays using diagnostic tests
containing normal human plasma demonstrated that HIP
peptide can compete with AT-III for Hep binding and neu-
tralize AT-III inhibition of both factor Xa (FXa) and thrombin
activity. Furthermore, HA-Hep showed an anticoagulant ac-
tivity '10 times higher than that of unfractionated Hep.
Finally, purified intact HIP from HEC cells, a human uterine
cell line, also inhibited the anticoagulant activities of the
AT-III–Hep complex. Therefore, these results suggest that
HIP may play a physiological role as a modulator of blood
coagulation.
MATERIALS AND METHODS
Materials. [3H]Hep (0.44 mCiymg; 1 Ci 5 37 GBq) was
purchased from DuPontyNEN. Dulbecco’s PBS was from
GIBCO. Imject activated immunogen conjugation kits were
purchased from Pierce. COATEST Heparin and COATEST
Antithrombin kits were purchased from Helena Laboratories.
AT-III-agarose, sodium chloride, potassium chloride, and
sodium phosphate were purchased from Sigma. All chemicals
used were reagent grade or better.
Peptide Synthesis and HIP Peptide Affinity Matrix. The
synthetic HIP peptide, derived from a segment of the predicted
amino acid sequence of HIP (7), CRPKAKAKAKAKDQTK,
was synthesized on a Vega 250 peptide synthesizer using
fluorenylmethoxycarbonyl (Fmoc) methodology (9). This syn-
thetic peptide was conjugated to maleimide-activated BSA
(Pierce) through the sulfhydryl group of cysteine in the peptide
following the coupling procedures provided by the manufac-
turer. HIP peptide affinity matrix was formed by cross-linking
the BSA-conjugated HIP peptide to cyanogen bromide-
activated Sepharose (Sigma) in the presence of N-acetylated
Hep. Inclusion of acetylated Hep was adopted to produce a
more stable affinity matrix by shielding the Hep binding sites
of the HIP peptide–BSA complex from cross-linking to the
Sepharose beads. Acetylation of Hep was performed following
the method previously described (10).
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HIP Peptide Affinity Chromatography. The HIP peptide
affinity matrix was packed into a 1-ml fast protein liquid
chromatography (FPLC) column (Pharmacia) and condi-
tioned by repeated washing in 10 mM phosphate buffer (pH
7.4) with a gradient of 0.15–4.0 M NaCl. Commercial [3H]Hep
was resuspended in 0.15 M NaCly10 mM phosphate, pH 7.4,
and loaded into the column. The column was eluted with a
linear gradient from 0.15 to 4.0 M NaCl in a 10 mM phosphate
buffer (pH 7.4) at a rate of 0.5 mlymin. Fractions of 0.5 ml were
collected, and aliquots were analyzed for radioactivity. Large-
scale fractions were performed on a 5 ml of HIP peptide
affinity matrix. [3H]Hep resuspended in 0.15 M NaCly10 mM
phosphate, pH 7.4, was loaded into the column. The column
then was washed sequentially with 0.15 M NaCly10 mM
phosphate, pH 7.4 (run-through Hep, or RT-Hep), and 0.45 M
NaCly10 mM phosphate, pH 7.4 (low-affinity Hep, or LA-
Hep), extensively. Finally, the column was eluted with 3.0 M
NaCly10 mM phosphate, pH 7.4 (HA-Hep). Radioactivity in
an aliquot (50 ml) from each fraction (1 ml per fraction) was
determined by liquid scintillation counting. Each of these
affinity classes of Hep was collected, extensively dialyzed
against doubly distilled, deionized H2O, lyophilized, and used
for further analysis.
Hep oligosaccharides were obtained by partial deaminative
cleavage of the polysaccharide with nitrous acid at pH 1.5 (11).
The reaction was allowed to proceed for 10 min and inter-
rupted by the addition of ammonium sulfamate in a 4-fold
molar excess over nitrite. The resulting mixture was separated
by gel permeation chromatography on a 1.5 3 170 cm Seph-
adex G-50 (superfine) column and eluted with 0.5 M
NH4HNO3 at a flow rate of 6.5 mlyhr. Fractions of 2.0 ml were
collected and uronic acid concentration of individual fraction
was determined by the carbazole method (12). The peaks
corresponding to tetra-, hexa-, octa- and decasaccharides, as
determined by elution positions relative to an internal [3H]oc-
tasaccharide standard, were pooled and reductively labeled
with [3H]NaBH4. Each size-fractionated mixture was repuri-
fied by a second round of gel permeation chromatography
performed under the identical conditions to eliminate possible
carryover from adjacent peaks. The eluted fractions were
analyzed for radioactivity and peak fractions representing
size-homogenous oligosaccharides were collected. Estimated
specific activity of the radiolabeled oligosaccharides was
2–20 3 104 dpmynmol. The [3H]Hep oligosaccharides were
loaded onto the HIP affinity matrix, and the column was
extensively washed with 1 M NaCly10 mM phosphate, pH 7.4.
Bound Hep oligosaccharides were eluted with 3 M NaCly10
mM phosphate, pH 7.4. Radioactivity in each fraction was
determined by liquid scintillation counting.
Determination of Size and Charge Density of Hep Species.
The size of the Hep fractions was analyzed on a 1 3 30 cm
Superose 12 column (Pharmacia) equilibrated and eluted with
2 M guanidine hydrochloride, 0.01% (wtyvol) octyl glucoside,
20 mMTris-acetate (pH 7.0), and 0.02% (wtyvol) sodium azide
at a flow rate of 0.7 mlymin at room temperature, with a back
pressure of '300 psi (1 psi 5 6.89 kPa). Fractions were
collected every 0.5 min, and the radioactivity was determined
by liquid scintillation counting.
The charge density of Hep fractions was analyzed by anion
exchange liquid chromatography on a 0.5 3 5 cm Mono Q
column (Pharmacia). Samples were loaded into a column
equilibrated with 0.5 M urea, 0.01% (wtyvol) octyl glucoside,
20 mM Tris-acetate (pH 7.0), and 0.02% (wtyvol) sodium
azide, and the column was eluted with a gradient of 0–4 M
NaCl in the same buffer. The column was pumped at a flow
rate of 1 mlymin at room temperature with a back pressure of
'450 psi. Fractions were collected every 0.5 min, and the
radioactivity determined by liquid scintillation counting.
AT-III and Basic Fibroblast Growth Factor (bFGF) Affinity
Chromatography. AT-III-agarose (Sigma) was resuspended in
10 mM phosphate (pH 7.4), packed into a 1-ml FPLC column,
and conditioned by repeated gradient washing of 0–2.0 M
NaCly10 mM phosphate, pH 7.4. Unfractionated [3H]Hep or
HA-Hep were loaded onto the AT-III-agarose column. Then
the column was washed with 10 mM phosphate (pH 7.4) and
eluted with a gradient of 0–2.0 M NaCl at a flow rate of 0.5
mlymin. Fractions of 0.5 ml were collected and analyzed for
radioactivity. Recombinant bFGF was coupled to CNBr-
activated Sepharose 4B in the presence of a 5-fold molar excess
of N-acetylated Hep to protect potential Hep-binding sites as
described (10). The bFGF affinity chromatography of unfrac-
tionated [3H]Hep and HA-Hep was performed using the
procedures described above for affinity chromatography on
AT-III-agarose.
Coagulation Assays. COATEST Heparin (for determina-
tion of Hep in plasma) and COATEST Antithrombin (for
determination of AT-III–Hep cofactor activity), were em-
ployed to examine the effect of HIP peptide on the antico-
agulatory activity of Hep andAT-III, respectively. Coagulation
assays were performed following the procedures provided by
manufacturer. The principle for determination of Hep con-
centration in plasma is as follows: (i) Hep1AT-III (excess)3
[AT-III–Hep]; (ii) [AT-III–Hep] 1 FXa (excess) 3 [AT-III–
Hep–FXa] 1 FXa (remaining); and (iii) S-2222 1 FXa (re-
maining)3 peptide 1 pNA (yellow). S-2222 (Bz-Ile-Glu-Gly-
Arg-pNA) is a chromogenic substrate susceptible to FXa (pNA
stands for p-nitroaniline). Briefly, standard samples including
normal human plasma, 0.1 unityml of AT-III, and varying
concentrations of Hep from 0.01 to 0.07 unityml (Elkins-Sinn,
Cherry Hill, NJ) were incubated at 378C for 3–4 min, then FXa
(0.355 nkat) kept at room temperature was added and mixed
well. The mixture was incubated at 378C for 30 sec and the
chromogenic substrate S-2222 (100mmol, 378C) was added and
mixed well. The mixture was further incubated at 378C for
exactly 3 min. The reaction was stopped by adding 20%
(volyvol) acetic acid. To test effect of HIP peptide, different
concentrations of HIP peptide were added to the standard
sample containing 0.07 unityml of Hep, and the Hep activity
was analyzed as described above. The principle for determi-
nation of AT-III–Hep cofactor activity in plasma is as follows:
(i) AT-III 1 Hep (excess)3 [AT-III–Hep]; (ii) [AT-III–Hep]
1 thrombin (excess) 3 [AT-III–Hep–thrombin] 1 thrombin
(residual); and (iii) S-22381 thrombin (residual)3 peptide1
pNA (yellow). S-2238 (H-D-Phe-Pip-Arg-pNA) is a chromo-
genic substrate susceptible to thrombin. Briefly, standard
samples containing normal human plasma at different dilu-
tions (creating varying concentrations of plasma AT-III) were
incubated, in the presence of Hep, at 378C for 3–6 min. Then,
thrombin was added (1.77 nkat) and mixed well, and the
solution further incubated at 378C for 30 sec. The S-2238
substrate was added and incubated at 378C for 30 sec. The
reaction was stopped with 20% (volyvol) acetic acid. To test
the effect of HIP peptide, different concentrations of HIP
peptide were added to the standard sample containing 100%
normal AT-III concentration ([Hep] ' 0.05 unityml), and the
assay was carried out as described above.
Determination of Anticoagulant Activities of Fractionated
Hep. Hep (1000 unitsyml; Elkins-Sinn) was fractionated in a
HIP peptide affinity column using stepwise elution as de-
scribed above resulting in three affinity classes of Hep: RT-
Hep, from HIP peptide affinity chromatography; LA-Hep,
low-affinity (0.45 M NaCl eluate) Hep from HIP peptide
affinity chromatography; and HA-Hep, high-affinity (3.0 M
NaCl eluate) Hep from HIP peptide affinity chromatography.
The anticoagulant activity of each Hep fraction was deter-
mined by FXa-dependent coagulation assay (COATEST Hep-
arin) as described above. Comparison of specific activities was
based upon the uronic acid content determined by carbazole
assay (12).
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RESULTS
A Subset of Hep Chains Bind to HIP Peptide with High
Affinity via a Small Oligosaccharide Motif. Commercial
[3H]Hep was fractionated by HIP peptide affinity chromatog-
raphy using salt gradient elution. Initial, continuous salt gra-
dient elutions revealed that most [3H]Hep appeared in the
run-through fractions (0.15 M NaClyPBS; RT-Hep) while
another portion of [3H]Hep bound to the column and eluted
at 0.3–0.4 MNaClyPBS elution (LA-Hep). A small percentage
of [3H]Hep ('1–5% of total [3H]Hep) bound to HIP peptide
affinity matrix tightly and eluted at 2.2 M NaCl (HA-Hep).
Large-scale preparations of three affinity classes of Hep for
further study were obtained using a stepwise elution procedure
with 0.15 M, 0.45 M, and 3.0 M NaCl (Fig. 1A). Rechromatog-
raphy of each affinity class of [3H]Hep after dialysis resulted
in near quantitative elution (.90%) at the salt concentration
used for the initial fractionation. These results suggest that
HIP peptide binds to a particular structural motif present only
in a subset of Hep molecules. To determine the minimum size
of the structural motif recognized by HIP, we tested the ability
of [3H]Hep oligosaccharides of different sizes to bind to the
HIP peptide affinity matrix. As shown in Fig. 1B, a small
percentage of both octa- and decasaccharides bound to HIP
peptide affinity matrix and eluted at.1.0 M NaCl, whereas no
high affinity binding of tetra- and hexasaccharides to HIP
peptide affinity matrix was detected. In generating the oligo-
saccharides, the N-sulfated glucosamine residue originally at
the reducing end is effectively destroyed. The next N-sulfated
glucosamine required would occur two residues in toward the
nonreducing terminus. Therefore, we conclude that the motif
recognized by HIP is contained in a penta- or hexasaccharide
of intact Hep molecules—i.e., the minimum size required for
AT-III binding (1–3).
HA-Hep Has a Larger Molecular Weight and Higher Neg-
ative Charge Density than Unfractionated Hep, RT-Hep, and
LA-Hep. To determine the average size and charge density of
FIG. 1. HIP peptide affinity chromatography of Hep and Hep oligosaccharides. (A) [3H]Hep dissolved in 0.15 MNaClyPBS, pH 7.4, was applied
to a 1-ml HIP peptide affinity FPLC column equilibrated with the same buffer (M). The column then was eluted first with 0.15 M NaCl then with
0.45 M or 3.0 M NaCl in PBS (indicated by vertical arrows) at a flow rate of 0.5 mlymin to generate RT-, LA-, and HA-Hep fractions, respectively.
Rechromatography of the high-affinity fraction (F) demonstrated quantitative rebinding and elution in the 3.0 M NaCl eluate. Each fraction (0.5
ml per fraction) was collected and radioactivity determined by liquid scintillation counting. (B) [3H]Hep oligosaccharide or [3H]Hep was
resuspended in 0.15MNaCly10mMphosphate, pH 7.4, and loaded onto a 1-ml HIP peptide affinity FPLC column equilibrated with 0.15MNaCly10
mM phosphate, pH 7.4. The column then was washed with 1.0 M NaCly10 mM phosphate, pH 7.4, extensively. Finally, the column was eluted with
3.0 M NaCly10 mM phosphate, pH 7.4. The percentage of [3H]Hep or [3H]Hep oligosaccharide binding to the column and eluting at .1.0 M NaCl
is shown. (C) Run-through [3H]Hep (RT-Hep,M), low-affinity [3H]Hep (LA-Hep, F), and high-affinity [3H]Hep (HA-Hep,m) isolated as described
above were analyzed on a Superose 12 column. The elution positions of blue dextran (Vo) and [3H]glucosamine (Vt) standards are indicated. (D)
Bulk [3H]Hep (E), LA-Hep (M), and HA-Hep (l) were analyzed by Mono Q anion exchange liquid chromatography column. The NaCl gradient
conditions are indicated by a dashed line.
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different HIP-binding Hep fractions, each affinity class of Hep
was subjected to gel permeation and ion exchange liquid
chromatography. HA-Hep has the largest median size when
analyzed on a column of Superose 12, LA-Hep has an inter-
mediate median size, and RT-Hep is enriched in smaller size
classes of Hep chains (Fig. 1C). Comparison of elution posi-
tions with polysaccharide standards indicate that the median
molecular weight of HA-Hep is '40,000—i.e., '4 times
greater than that of unfractionated Hep (median molecular
weight of 10,000). Thus, HA-Hep is enriched in larger species
of Hep chains. Results of anion exchange chromatography
indicate that HA-Hep also has a slightly higher average
negative charge density than either LA-Hep or unfractionated
Hep (Fig. 1D), indicating that the Hep chains selectively
recognized by HIP peptide may have an unusually high sulfate
density. Collectively, these results indicate that HA-Hep
chains differ, both in terms of size and charge, from unfrac-
tionated and other HIP peptide affinity classes of Hep.
HA-Hep Contains Polysaccharide Structures Recognized
by AT-III with High Affinity and Is Highly Enriched in
Anticoagulant Activity. Since HIP peptide recognizes a spe-
cific structural motif in Hep, it was of interest to determine if
similar structural features were required for Hep binding to
other Hep-binding proteins, such as AT-III or bFGF (1, 3,
13–15). Therefore, HA-Hep was subjected to both AT-III and
bFGF affinity chromatography. HA-Hep was not enriched in
species that specifically bound to bFGF affinity matrix with
high affinity (Fig. 2A). In contrast, HA-Hep almost quantita-
tively bound to AT-III affinity matrix and was eluted as a single
homogeneous peak at 0.86 M NaCl. As shown in Fig. 2B,
AT-III affinity chromatography of unfractionated [3H]Hep
resulted in several distinct fractions—i.e., one eluting at the
run-through and another eluting at 0.6 M NaCl with two
smaller peaks at 0.4 M NaCl and 0.86 M NaCl. Thus, HA-Hep
is highly enriched in Hep species that bind to AT-III with
highest affinity. These observations suggest that the same or
similar Hep motif(s) are recognized by both HIP peptide and
AT-III. Therefore, the structural requirements for high affin-
ity Hep binding to HIP peptide and bFGF appear to be
distinct. Hep octasaccharides, which bound to HIP peptide
with high affinity, also were greatly enriched for species that
bound to AT-III with high affinity. Approximately 50% of
these octasaccharides bound to AT-III-agarose and required
more than 0.45 M NaCl for elution (data not shown). These
observations suggest that HA-Hep contains specific sequence
motifs critical for high-affinity binding to both HIP peptide
and AT-III.
Since the anticoagulant activity of Hep primarily is exerted
via binding to and activation of AT-III, it was of interest to
determine the specific anticoagulant activity of Hep fractions
obtained by HIP peptide affinity chromatography. To this end,
we used a FXa-dependent coagulation assay kit. As shown in
Fig. 3, HA-Hep displayed the highest anticoagulant activity
and was at least 10-fold more potent than unfractionated Hep
on a mass basis. Since the median size of HA-Hep is '4 times
that of unfractionated Hep, anticoagulant activity of HA-Hep
is at least 40-fold higher on a molar basis; however, larger Hep
chains are more likely to have multiple high-affinity binding
sites than smaller chains and so may further increase the
apparent specific activity. LA-Hep also had higher anticoag-
ulant activity than that displayed by unfractionated Hep. This
activity was consistently lower than that of HA-Hep, but may
not be significantly different. RT-Hep had marginal anticoag-
ulant activity. Collectively, these results demonstrate that
HA-Hep contains Hep molecules with exceptionally high
anticoagulant activity.
HIP Peptide and Purified HIP Antagonize AT-III–Hep
Actions on Blood Coagulation Activities. Based on the above
observations, it was hypothesized that HIP peptide competes
with AT-III for Hep binding and might modulate the antico-
agulant activity of the polysaccharide. To test this, both FXa-
and thrombin-dependent coagulation assays were used. As
shown in Fig. 4A, the addition of HIP peptide in the presence
of the AT-III–Hep complex restored FXa-dependent activity
in a concentration-dependent and saturable manner. Full
restoration of FXa activity was achieved at a HIP peptide
concentration of 150 mgyml. A scrambled sequence of this
peptide (CKDKTKPRAKQAAAKK) had no significant ef-
fect on activity. Furthermore, HIP peptide alone at the same
FIG. 2. bFGF and AT-III affinity chromatography of bulk Hep and
HA-Hep. (A) Unfractionated [3H]Hep (F) or HA-Hep (M) were
resuspended in PBS (pH 7.4) and then loaded onto a 1-ml bFGF
affinity FPLC column equilibrated in PBS (pH 7.4). The column was
eluted with a gradient of 0–2 M NaCly10 mM phosphate, pH 7.4
(dashed line), at a flow rate of 0.5 mlymin. Each fraction (0.5 ml per
fraction) was collected and radioactivity determined by liquid scintil-
lation counting. (B) Unfractionated [3H]Hep (F) or HA-Hep (M)
resuspended in PBS (pH 7.4) was loaded onto a 1-ml AT-III affinity
FPLC column equilibrated in PBS (pH 7.4). The column was eluted
with a gradient of 0–2 M NaCly10 mM phosphate, pH 7.4 (dashed
line), at a flow rate of 0.5 mlymin. Each fraction (0.5 ml per fraction)
was collected, and radioactivity was determined by liquid scintillation
counting.
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or higher concentrations in the absence of FXa did not result
in any color reaction (data not shown). Therefore, HIP peptide
appears to functionally compete with AT-III for Hep binding
and inhibit the formation of Hep–AT-III–FXa complexes.
Similarly, thrombin activity was restored by HIP peptide.
Again, this effect was HIP peptide concentration-dependent
up to 1 mgyml (Fig. 4B). Furthermore, purified HIP (S.L. and
D.D.C., unpublished work) also was able to restore, in a
dose-dependent fashion, FXa activity in the presence of AT-III
and maximally inhibitory doses of Hep (0.07 unityml). Col-
lectively, these results demonstrate that HIP and HIP peptide
effectively antagonize AT-III–Hep complex actions in blood
coagulation events.
DISCUSSION
Our results demonstrate that HIP peptide specifically recog-
nizes AT-III-binding Hep species and modulates blood coag-
ulation activities. Previous studies by Bae et al. (16) have shown
specific recognition of Hep motifs by a synthetic peptide
corresponding to amino acids 123–139 of AT-III. This is the
first demonstration of a non-AT-III-derived synthetic peptide
recognizing a specific structural motif in Hep. The apparent
high affinity between HIP peptide and HA-Hep is particularly
remarkable considering the simple structure of the 16-aa
peptide. Protein structure-predicting algorithms predict that
HIP peptide would occur in an a-helical domain of the intact
protein. Interestingly, biophysical studies indicate that helix-
forming peptides optimally promote interactions with Hep,
although interactions with particular Hep motifs were not
identified in these studies (17). Therefore, studies of the
interaction of native and modified HIP peptide with Hep may
provide important information on the structure–function re-
lationships of interacting proteins and Hep motifs.
The interaction between AT-III and Hep has been studied
extensively (18, 19). A unique pentasaccharide sequence in
Hep is specifically recognized by AT-III (1, 3, 15). Since the
procedure used to generate Hep oligosaccharides destroys
glucosaminyl residues at the reducing terminus, the present
studies indicate that HIP peptide also recognizes a motif of five
to six saccharide units. Furthermore, Hep oligosaccharides
that bind to HIP peptide with high affinity also bind to AT-III
with high affinity. If the motif in Hep required for high-affinity
binding to HIP peptide is indeed larger than a pentasaccha-
ride, it appears that the additional monosaccharide unit also
facilitates AT-III binding, since HA-Hep represents a subset of
HA-Hep–AT-III with particularly high affinity for the pro-
tease inhibitor. Furthermore, the anticoagulant activity of
HA-Hep is at least 10- to 40-fold higher than that of unfrac-
tionated Hep. Uncertainty exists in the exact degree in in-
crease in specific activity of HA-Hep, since this fraction is
larger than unfractionated Hep, tending to further increase
this value. On the other hand, larger Hep chains may contain
more than one high-affinity binding site, which might lower the
specific activity when considered on a per-site basis. In any
case, HA-Hep is substantially enriched for anticoagulant
activity and with regard to affinity for AT-III–Sepharose.
FIG. 3. Anticoagulant activity of different affinity classes of Hep
selected by HIP peptide affinity chromatography. FXa-dependent
chromogenic reaction was performed as described. Bulk (M), RT-Hep
(l), LA-Hep (F), and HA-Hep (L) were added to the assay at the
indicated concentrations (uronic acid content). The concentration of
36.25 ngyml (uronic acid content) of unfractionated Hep is equivalent
to 0.01 unityml of bulk Hep. Results are means of duplicate deter-
minations with SDs ,15%.
FIG. 4. HIP peptide antagonizes Hep action in FXa- and thrombin-
dependent coagulation assays. The FXa- and thrombin-dependent
chromogenic reaction was performed as described. Data are expressed
as the percentage of the AT-III–Hep complex inhibitable enzymatic
activity in each assay. All reactions were performed in the presence of
0.1 unityml of AT-III and 0.07 unityml Hep and the indicated HIP
peptide concentrations. Results are means of duplicate determinations
with SDs ,15%. (A) FXa activity. (B) Thrombin activity.
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Cell surface-expressed HIP has been suggested to be in-
volved in HepyHS-dependent cell–cell or cell–extracellular
matrix interactions (7, 8). Results of the current study suggest
another possible function of HIP, namely, modulation of blood
coagulation activities. Since both purified HIP and HIP pep-
tide compete with AT-III for Hep binding and modulate
coagulation events, it is likely HIP also competes with AT-III
for Hep binding in vivo. HIP is expressed by most human
epithelial cells and cell lines as well as normal human umbilical
vein vascular endothelial cells (7) and is not secreted to an
appreciable extent (8). Therefore, under normal situations,
cell surface HIP can participate in cell–cell or cell–matrix
interactions of the expressing cell. When tissue injury occurs,
HIP may be released locally into the injured area, where it
competes with AT-III for HSyHep binding and neutralizes the
anticoagulant AT-III–HSyHep complex. Consequently, a
higher activity of coagulant proteases would be available at
sites of injury. Moreover, HIP also may cooperate with other
adhesion proteins to facilitate cell binding to the injured
endothelium or epithelium through its HSyHep-binding func-
tion. Collectively, these actions might accelerate the recovery
of the injured area. Blood coagulation has long been a major
area of research, and new factors continue to be identified (2,
4, 5, 20, 21). The evidence that HIP and HIP peptide antag-
onize Hep action and modulate coagulation events suggests
that HIP might be a novel modulator of the coagulation
cascade.
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